TABLE 2.
Outcomes to single agent TKIs in BP CML
| TKI | Prior TKI (yes/no) | Reference(s) | No. of patients | CHR (%) | CCyR (%) | alloHSCT (%) | Median OS (mo) |
|---|---|---|---|---|---|---|---|
| Imatinib | No | 37 |
mBP = 38 lBP = 20 |
10.5 20 |
7.9 10 |
4.5 N/A |
N/A N/A |
| No | 40, 41 | 229 (mBP) | 15.3 | 7.4 | 5 | 6.9 | |
| No | 38 | 75 | 21.3 | 18.7 | 9.3 | 6.5 | |
| No | 42 | 30 | 33 | 0 | N/A | OS 36% at 1 year | |
| No | 39 | 92 | 26.1 | 9.8 | 9.8 | 7.0 | |
| Dasatinib | Yes | 47 |
mBP = 23 lBP/Ph+ALL = 10 |
34.8 70 |
26.1 30 |
N/A 10 |
N/A N/A |
| Yes | 43, 46 |
mBP = 149 lBP = 61 |
17.4 18.0 |
17.5 36.8 |
6.0 9.8 |
7.7–7.9 9.0–11.4 |
|
| Nilotinib | Yes | 45 | 33 | 6.1 | 6.1 | N/A | N/A |
| Yes | 44 |
mBP = 105 lBP = 31 |
24 21 |
30 32 |
11 6 |
10.1 7.9 |
|
| Yes | 51 |
mBP = 133 lBP = 50 |
6.8 14.0 |
8.3 26.0 |
N/A N/A |
OS 63% at 18 months for mBP/lBP | |
| Bosutinib | Yes | 49 |
Second line = 36 ≥Third line = 28 |
27 4 |
37 17 |
N/A N/A |
11.2 8.9 |
| Ponatinib | Yes | 48, 52 | 62 (incl. 24 with T315I) | 21 | 17.4 | 9.7 | OS 29% at 1 year & 9% at 3 years |
Abbreviations: alloHSCT, allogeneic haemopoietic stem cell transplantation; BP, blast phase; CCyR, complete cytogenetic remission; CHR, complete haematologic remission; CML, chronic myeloid leukaemia; lBP, lymphoid blast phase; mBP, myeloid blast phase; N/A, data not available; OS, overall survival; Ph+ALL, Philadelphia chromosome‐positive acute lymphoid leukaemia; TKI, tyrosine kinase inhibitor.